A weight-loss drug you wouldn't need to take indefinitely

Amgen is trying a unique strategy with its obesity drug candidate

February 5, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down Amgen is testing whether it can wean patients toward lower or less frequent doses of its obesity drug candidate. By Elaine Chen STAT+ | Diabetes treatments have improperly listed patents that should be removed, analysis finds Drugmakers "appear to be using these device patents as part of a strategy to delay competition," said analysis co-author William Feldman. By Ed Silverman STAT+ | Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production The deal could help Novo Nordisk produce more of its wildly popular obesity drug Wegovy, as well as its diabetes medicine Ozempic. By Andrew Joseph Adobe Let the Medicare Advantage lobbying begin The big takeaway from CMS' newest proposals for Medicare Advantage: the Biden administration didn't want to rock the boat in an election year. By Bob Herman Texas Medicaid agrees to fully cover gene therapy for Afghan refugees' infant After initially balking, Texas officials have agreed to pay for the multimillion-dollar treatment for a rare genetic disorder. By Megan Molteni STAT+ | New Medicare Advantage rule is boon for providers, drag on insurers A new federal rule requires Medicare Advantage plans to pay for inpatient care if a doctor says the patient has to stay for two midnights. By Tara Bannow Molly Ferguson for STAT STAT+ | Novo's Catalent deal is great for GLP-1s. But what about drug manufacturing? The question is this: Should companies rent access to manufacturing plants or should they own them outright? By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser